| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 01/15/2003 | EP0671927B1 Human neutralizing monoclonal antibodies to respiratory syncytial virus |
| 01/15/2003 | EP0584347B1 Enantiomeric hydroxylated xanthine compounds |
| 01/15/2003 | CN1391570A Phenyl-and pyridyl-tetrahydro-pyridines having TNF inhibiting activity |
| 01/15/2003 | CN1391564A Chemical compounds |
| 01/15/2003 | CN1391556A IL-8 receptor antagonists |
| 01/15/2003 | CN1391481A 疫苗 Vaccine |
| 01/15/2003 | CN1391480A Compositions and methods for treatment of allergic disorders |
| 01/15/2003 | CN1391475A Optically active isomers of ketotifen and therapeutically active metabolites thereof |
| 01/15/2003 | CN1391473A VLA-4 inhibitor compounds |
| 01/15/2003 | CN1390587A Medicine for treating throat disease |
| 01/15/2003 | CN1390577A Pill of tortoise plastron and turtle shell |
| 01/15/2003 | CN1390576A Exterior-applied medicine for treating rhinitis and nasosinusitis |
| 01/15/2003 | CN1098695C Chinese medicinal composition for treating asthma and preparing process thereof |
| 01/15/2003 | CN1098686C Use of xanthine derivatives for reducing pathological hyper-reactivity of eosinophilic granulocytes, xanthine compounds and process for producing them |
| 01/15/2003 | CN1098680C Suspending liquid for spray and preparing method thereof |
| 01/14/2003 | US6506912 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 01/14/2003 | US6506891 Cell surface molecule-induced macrophage activation |
| 01/14/2003 | US6506874 Hypoglycemic agents; obesity, nervous system, cardiovascular, and kidney disorder treatment |
| 01/14/2003 | US6506802 Disulfide derivatives useful for treating allergic diseases |
| 01/14/2003 | US6506779 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 01/14/2003 | US6506773 Hydroxamic and carboxylic acid derivatives |
| 01/14/2003 | US6506772 Pharmaceutically active salts thereof with activity as adenosine receptor ligands are disclosed. These compounds are the adenosine receptor. |
| 01/14/2003 | US6506764 Hydroxamic and carboxylic acid derivatives |
| 01/14/2003 | US6506762 Certain alkylene diamine-substituted heterocycles |
| 01/14/2003 | US6506756 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 01/14/2003 | US6506750 Morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/14/2003 | US6506740 Compounds that can be substituted at the 7, 8, and/or 9 positions and methods for preparing the 4- dedimethylamino tetracycline compounds. Other tetracycline compounds are the 4-dedimethylaminotetracycline derivatives with an oxime |
| 01/14/2003 | US6506731 Elastin peptide analogs and methods of using same |
| 01/14/2003 | US6506582 Extended by aspartic acid at 5' end and shortened at 3' end by one to eight amino acids; nonimmunogenic; binds CD4 lymphocytes |
| 01/14/2003 | US6506411 Anti-angiogenic compositions and methods of use |
| 01/14/2003 | US6506383 Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies |
| 01/09/2003 | WO2003002722A2 T cell regulatory genes and methods of use thereof |
| 01/09/2003 | WO2003002566A1 Purine derivatives as a2b adenosine receptor antagonists |
| 01/09/2003 | WO2003002561A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | WO2003002559A2 Piperidine compounds for use as orexin receptor antagonist |
| 01/09/2003 | WO2003002554A1 Piperazine compounds |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002540A1 Cyclic diamine compound having five-membered cyclic group |
| 01/09/2003 | WO2003002539A1 Dibenzocycloheptene compound |
| 01/09/2003 | WO2003002537A1 Bis(5-aryl-2-pyridyl) derivative |
| 01/09/2003 | WO2003002535A1 Cyclic diamine compounds bearing six-membered cyclic groups |
| 01/09/2003 | WO2003002532A1 Cyclic diamine compounds having fused-ring groups |
| 01/09/2003 | WO2003002530A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002522A1 Peptide deformylase inhibitors |
| 01/09/2003 | WO2003002511A1 Cycloalkenone derivative |
| 01/09/2003 | WO2003002152A2 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 01/09/2003 | WO2003002140A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 01/09/2003 | WO2003002130A1 Fat-binding polymers |
| 01/09/2003 | WO2003002127A1 Use of at least one glycoinhibitor substance |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002111A1 Inhalation particles |
| 01/09/2003 | WO2003002109A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | WO2003002106A2 Use of tyrosine kinase inhibitions for treating allergic diseases |
| 01/09/2003 | WO2003002098A1 Tablet comprising cetirizine and pseudoephedrine |
| 01/09/2003 | WO2003002093A1 Olopatadine formulations for topical administration |
| 01/09/2003 | WO2002072536A8 Urea derivatives having vanilloid receptor (vr1) antagonist activity |
| 01/09/2003 | WO2002064594A3 6-substituted pyrido-pyrimidines |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002044320A3 Human elongase genes and uses thereof |
| 01/09/2003 | WO2002042437A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 01/09/2003 | WO2002034236A3 Lipid formulations for target delivery |
| 01/09/2003 | WO2002009716A3 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001072728B1 Novel piperazine derivatives |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | WO2001055336A9 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/09/2003 | US20030008915 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents |
| 01/09/2003 | US20030008908 Isoxazoline compounds having MIF antagonist activity |
| 01/09/2003 | US20030008906 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 01/09/2003 | US20030008901 For therapy of arthritis, cancer, and other diseases characterized by matrix metalloproteinase or mammalian reprolysin activity |
| 01/09/2003 | US20030008893 For prophylaxis and therapy of diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation |
| 01/09/2003 | US20030008886 For therapy of pain |
| 01/09/2003 | US20030008877 CCR5 antagonists useful for treating AIDS |
| 01/09/2003 | US20030008872 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors |
| 01/09/2003 | US20030008868 Compounds useful as anti-inflammatory agents |
| 01/09/2003 | US20030008867 Compounds |
| 01/09/2003 | US20030008834 Compsoitions and methods for treating epithelia and retinal tissue diseases |
| 01/09/2003 | US20030008829 For therapy and prophylaxis of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis, psoriasis |
| 01/09/2003 | US20030008293 Detection of polymorphism in preferential nucleotide sequences; obtain cells, extract nucleotide sequences, incubate with probe, detect signal, monitor hybridization pattern |
| 01/09/2003 | US20030008023 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | US20030007966 Adult respiratory distress syndrome |
| 01/09/2003 | US20030007963 Treatment of pompe's disease |
| 01/09/2003 | US20030007932 Drug delivery; overcoated solid dried active solid |
| 01/09/2003 | CA2490219A1 Fat-binding polymers |
| 01/09/2003 | CA2452371A1 Use of tyrosine kinase inhibitors for treating allergic diseases |
| 01/09/2003 | CA2452364A1 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 01/09/2003 | CA2452361A1 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | CA2452196A1 T cell regulatory genes and methods of use thereof |
| 01/09/2003 | CA2452105A1 Dibenzocycloheptene compound |
| 01/09/2003 | CA2451464A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | CA2451128A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451125A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/08/2003 | EP1273659A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/08/2003 | EP1273580A1 Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents |
| 01/08/2003 | EP1273576A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273305A1 Medical preparation for inhalation comprising Antithrombin for treating inflammatory lung diseases and ARDS |